comparemela.com
Home
Live Updates
ELGAN Pharma Awarded $2.5 Million EU Grant to Support Phase III Registrational Study of ELGN-GI for the Treatment of Intestinal Malabsorption in Preterm Infants : comparemela.com
ELGAN Pharma Awarded $2.5 Million EU Grant to Support Phase III Registrational Study of ELGN-GI for the Treatment of Intestinal Malabsorption in Preterm Infants
/PRNewswire/ -- Elgan Pharma, a late-stage clinical biopharmaceutical company focusing on innovative treatments for critical conditions in neonates, announced...
Related Keywords
Israel
,
Tsipi Haitovsky
,
Elgan Pharma
,
Prnewswire Elgan Pharma
,
Miki Olshansky
,
European Innovation Council
,
Gastrointestinal Complications
,
comparemela.com © 2020. All Rights Reserved.